▶주메뉴 바로가기
▶본문 바로가기
South Korean drugmaker Daewoong Pharmaceutical said Oct, 2 it has won approval from European authorities for the sale of its botulinum toxin product. The European Commission accepted Daewoong’s a...
Samsung BioLogics has won a lawsuit against Switzerland-based Lonza to nullify its patents involving its cell line development technology in South Korea, according to sources Oct. 1. The court noted...
South Korean biotech firm Genexine announced on Sept. 27 that it has signed a contract with the Thai company KinGen Holdings to establish a 50:50 joint venture named KinGen Biotech. KinGen Holdings ...
Celltrion Healthcare on Sept. 27 announced its decision to expand sales in the Middle East. He company has got approval to exclusively supply Remsima, its version of Johnson & Johnson’s Remicade fro...
Celltrion Group on Sept. 20 announced that European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended giving sales approval for Remsima SC. CHMP is responsible for pr...
Medytox has participated in the seed-funding round of US startup LifeSprout, according to industry sources on Sept. 16. Although the Korean company declined to confirm the specific amount that it ha...
Korean pharmaceutical companies are making inroads into the Central and South American markets, betting on their steady growth. Samsung Bioepis, Celltrion Healthcare, Boryung Pharmaceutical, CJ Heal...
South Korean biopharmaceutical firm Celltrion announced Sept. 10 that its breast cancer biosimilar has been approved for sales in Canada. The regulatory body Health Canada has approved the data from...
South Korea’s Supreme Court has approved a grace period for Samsung BioLogics to defer the implementation of penalties imposed by the financial authorities by up to 30 days, the biopharma firm said...
Celltrion Group expects to receive approval for biosimilar Remsima SC from European authorities for sales before the end of this year, founder and Chairman Seo Jung-jin said at a bio conference on A...
South Korea’s Boryung Pharmaceutical announced on Aug. 27 it had received approval from the US Food and Drug Administration to start a phase 1 clinical trial of its drug candidate BR2002 The phase 1...
The Korea Exchange, South Korea’s stock market operator, on Aug. 26 announced its decision to delist troubled Kolon Group ’s US gene therapy-developing unit Kolon TissueGene . In late March, a c...
Celltrion in May established Celltrion Biopharma, its first unit in Ireland, for further expansion in the European biosimilar market, according to industry sources on Aug. 20. At the new unit, the ...
South Korean bio company OliPass has decided to inject 1.2 billion won ($988,000) to establish a unit in the US, according to industry sources on Aug 12. The company hopes to further strengthen its ...
Korean pharmaceutical company Yuhan announced on Aug. 7 that it has established new unit in Australia to expand its presence further globally. “We established Yuhan ANZ in Australia to focus more on...
Proptech startup Kasa Korea attracts W9.2b in series B funding
Korean lenders struggle with New York hotel-retail project investment
Netmarble launches storytelling game BTS Universe Story, second collaboration with BTS
Coupang delves into computer parts biz, outcompeting go-betweens
How once rising sports platform TLX Pass fell
W520b per BTS member? Market worth of K-pop stars in limelight as agency’s IPO nears
Litigations pile pressure on Mirae Asset Group
LG Chem to decide acquisition of Nissan factory in Spain within this month
September 28, 2020
